使用以米托蒽醌为基础的联合化疗方案作为晚期乳腺癌的一线治疗。
Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
作者信息
Bezwoda W R, Hesdorffer C S, Dansey R D
机构信息
Department of Medicine, University of the Witwatersrand, Johannesburg.
出版信息
S Afr Med J. 1987 Oct 3;72(7):465-7.
Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.
研究了三种含米托蒽醌的一线联合化疗方案用于治疗晚期乳腺癌。第一种联合方案由甲氨蝶呤、米托蒽醌（诺维本）和5-氟尿嘧啶组成（MNF），缓解率为17/48（35%）。环磷酰胺+米托蒽醌（CN）的缓解率为20/31（64%），而环磷酰胺+米托蒽醌+长春新碱（CNV）的缓解率为28/39（72%）。三种方案的缓解持续时间分别为：MNF为6个月，CN为7.5个月，CNV为11.5个月。这些方案耐受性良好，副作用发生频率大致相同。心脏毒性不常见，在118例研究患者中仅2例出现。
Zotero 插件